Subtype
Malignant Large Intestinal Neoplasm
CI-CAN-00003173Explore in graph →
1,622 active trials21 approved drugs383 evidence items
- NCIt
- C215202
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003173Explore in graph →
Clinical trials
7,502 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (742)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07649473 | QL1706 Combined With Standard Therapy for Conversion Therapy of Synchronous Liver Metastases From Colon Cancer: a Multicenter, Single-arm, Exploratory Study | not yet recruiting | Phase 2 | 30 | Fujian Medical UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651007 | Short-course RT Followed by NALIRIFOX Plus Pucotenlimab as Neoadjuvant Therapy for High-risk Locally Advanced Rectal Cancer With MSS/pMMR | not yet recruiting | Phase 2 | 29 | Wang XinOTHER | 0 | Jun 16, 2026 |
| clinicaltrials |
| NCT05358249 | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-03) | active not recruiting | Phase 1 / Phase 2 | 74 | Novartis PharmaceuticalsINDUSTRY | 8 | Jun 15, 2026 | clinicaltrials |
| NCT07646639 | Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC(PRIDE-02) | recruiting | Phase 2 | 122 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT04616183 | LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 46 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04729322 | Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05239546 | Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers(NAIO) | recruiting | Phase 2 | 25 | University of IowaOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05576896 | Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory | terminated | Phase 2 | 7 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | recruiting | Phase 2 | 20 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06051695 | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression(EVEREST-2) | recruiting | Phase 1 / Phase 2 | 474 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07011576 | A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (FRUITFUL)(FRUITFUL) | recruiting | Phase 2 | 60 | SCRI Development Innovations, LLCOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07612007 | HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization | not yet recruiting | Phase 2 | 80 | Mayo ClinicOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07644286 | A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer | recruiting | Phase 2 | 48 | Tao ZhangOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07645118 | Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer(IMPERIA) | not yet recruiting | Phase 2 | 10 | Dr. Te VuongOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04017650 | Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | active not recruiting | Phase 1 / Phase 2 | 38 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04771520 | Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors | recruiting | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04587128 | Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC | active not recruiting | Phase 2 | 34 | University of Wisconsin, MadisonOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT06050707 | MR-Adaptive Radiation Therapy for Anal Cancer With EScalated-Treatment in a Risk-Optimized Approach(MAESTRO) | recruiting | Phase 2 | 80 | University Health Network, TorontoOTHER | 3 | Jun 10, 2026 | clinicaltrials |
| NCT05319314 | LYL273 for Patients With Relapsed or Refractory mCRC(CARABiNER) | recruiting | Phase 1 / Phase 2 | 155 | Lyell Immunopharma, Inc.INDUSTRY | 1 | Jun 9, 2026 | clinicaltrials |
| NCT03947385 | Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | recruiting | Phase 1 / Phase 2 | 336 | IDEAYA BiosciencesINDUSTRY | 3 | Jun 8, 2026 | clinicaltrials |
| NCT06307548 | Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 21 | Roswell Park Cancer InstituteOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03781323 | Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer | active not recruiting | Phase 2 | 12 | University of RochesterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT00492999 | Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver | active not recruiting | Phase 2 | 64 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05546476 | Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15(PROACC-1) | completed | Phase 2 | 187 | PfizerINDUSTRY | 11 | Jun 3, 2026 | clinicaltrials |
| NCT07281157 | Liposomal Irinotecan, Capecitabine and Enlonstobart With Short-Course Radiotherapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07622550 | A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Serplulimab and Chemotherapy as First-line Treatment for Patients With RAS/BRAF-mutated Advanced Colorectal Cance | not yet recruiting | Phase 2 | 80 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07621497 | FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II) | not yet recruiting | Phase 2 | 229 | Sun Yat-sen UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07622017 | KORTUC (KRC-01) Plus Radiotherapy for Organ Preservation in Rectal Cancer(K-BOOST) | not yet recruiting | Phase 2 | 24 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT03935893 | Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers | active not recruiting | Phase 2 | 20 | Udai KammulaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05411718 | A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06680739 | Single cEll pRofiling PErsistaNce To ImmuNothErapy(SERPENTINE) | recruiting | Phase 2 | 60 | Vall d'Hebron Institute of OncologyOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06598007 | A Study to Determine the Effect of CT3001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 78 | Crossignal Therapeutics, Inc.INDUSTRY | 1 | May 29, 2026 | clinicaltrials |
| NCT00159484 | Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 75 | University of Southern CaliforniaOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT07223047 | A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 252 | Bristol-Myers SquibbINDUSTRY | 3 | May 28, 2026 | clinicaltrials |
| NCT07176182 | Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression | recruiting | Phase 2 | 236 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT02350530 | FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type(FORBES) | completed | Phase 2 | 138 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03548961 | Organ Preservation in Early Rectal Cancer Patients | active not recruiting | Phase 2 | 19 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04503694 | Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer(REGINA) | active not recruiting | Phase 2 | 72 | Jules Bordet InstituteOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06890624 | mFOLFOXIRI Plus PD-1 Inhibitor vs mFOLFOX6 as Neoadjuvant Therapy for Locally Advanced Colon Cancer(OPTICAL-3) | not yet recruiting | Phase 2 | 138 | Sun Yat-sen UniversityOTHER | 0 | May 22, 2026 | clinicaltrials |
| NCT06903858 | Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer(PICC-3) | recruiting | Phase 2 | 105 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07462143 | A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorectal Cancer | recruiting | Phase 2 / Phase 3 | 80 | RemeGen Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07604909 | A Phase II Randomized Trial of Serplulimab With Second-Line Chemo/Targeted Therapy for Early Relapse Colorectal Cancer After Adjuvant Chemotherapy | recruiting | Phase 2 | 40 | Fudan UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06959550 | Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer | recruiting | Phase 2 | 90 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07587619 | Intraoperative Use of Oxygen Saturation Imaging to Assess Intestinal Perfusion | active not recruiting | Phase 1 / Phase 2 | 52 | University of Southern CaliforniaOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT03745326 | Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | May 19, 2026 | clinicaltrials |
| NCT07359456 | Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases(COLIBRI-GI) | not yet recruiting | Phase 2 | 130 | UNICANCEROTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07594925 | Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial | recruiting | Phase 2 | 130 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 19, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 16, 2026source: clinicaltrials